abstract |
The present invention provides a cellular immunotherapy for genetically engineered redirected immune cells and B cell mediated autoimmune diseases. A genetically engineered CD19-specific redirecting immunity expressing a cell surface protein having an extracellular domain containing a receptor specific for CD19, an intracellular signaling domain, and a transmembrane domain The use of said cells to inhibit cells, CD19 + malignant cell immunotherapy and harmful B cell function, and electroporation with naked DNA encoding said receptors, A method of producing redirected T cells that express. [Selection figure] None |